Evaluation of peptide designing strategy against subunit reassociation in mucin 1: A steered molecular dynamics

J Lesitha Jeeva Kumari1, R Jesu Jaya Sudan1, C Sudandiradoss1

  • 1Department of Biotechnology, School of Biosciences and Technology, VIT University, Vellore, India.

Plos One
|August 18, 2017
PubMed

Insights

Designing peptide inhibitors targeting mucin 1 (MUC1) reassociation is key to breast cancer therapy. Receptor-based peptides show the highest binding affinity, offering a promising strategy to block MUC1 activation and alter disease progression.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cancer Research

Background:

  • Mucin 1 (MUC1) is a critical breast cancer tumor marker.
  • Subunit reassociation of MUC1 is essential for its cytoplasmic activation.
  • Inhibiting MUC1 heterodimeric association could alter breast cancer progression.

Purpose of the Study:

  • To evaluate peptide inhibitor design strategies against MUC1 receptor-ligand interactions.
  • To identify effective antagonists for MUC1 subunit reassociation.

Main Methods:

  • Design of peptides based on native residues, subunit interface, and secondary structure.
  • Docking studies of peptides with the MUC1 receptor subunit.
  • Evaluation of binding affinities using steered molecular dynamics and umbrella sampling.

Main Results:

  • Receptor-based peptides exhibited the highest binding affinity for MUC1.
  • MUC1 receptor-ligand alliance specificity was confirmed.
  • Peptide ligand stabilization relied on native residue inter-protein interactions.
  • Receptor-derived peptides showed consistent binding affinity, pull force, and free energy barriers.

Conclusions:

  • Peptide inhibitors targeting MUC1 subunit association can be designed based on native interactions.
  • Receptor-based peptides are most effective in inhibiting MUC1 heterodimeric reassociation.
  • These findings provide a foundation for developing efficient peptide inhibitors against MUC1.

Related Concept Videos